Quantcast

Uroplasty To Participate In The ROTH 26th Annual Conference - abc27 WHTM

Uroplasty To Participate In The ROTH 26th Annual Conference

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE Uroplasty, Inc.

MINNEAPOLIS, Feb. 26, 2014 /PRNewswire/ -- Uroplasty, Inc. (NASDAQ: UPI), a medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions, today announced that it will participate in the 26th Annual ROTH Conference on Tuesday, March 11, 2014. Rob Kill, President and CEO, and Brett Reynolds, Chief Financial Officer, will present at 8:30am PT and meet with investors one on one at the conference at the Ritz Carlton in Laguna Niguel, CA.

Attendance at the conference is by invitation only.  A live webcast of the presentation with accompanying slides will be broadcast via the Internet. Those interested in joining the webcast may access it through Uroplasty's website at www.uroplasty.com. An archived replay of the presentation will be available for 90 days following the event.

About Uroplasty, Inc.
Uroplasty, Inc., headquartered in Minnetonka, Minnesota, with wholly-owned subsidiaries in The Netherlands and the United Kingdom, is a global medical device company that develops, manufactures and markets innovative proprietary products for the treatment of voiding dysfunctions. Our focus is the continued commercialization of our Urgent® PC Neuromodulation System, the only commercially available, FDA-cleared system that delivers percutaneous tibial nerve stimulation (PTNS) for the office-based treatment of overactive bladder (OAB). OAB is a chronic condition that affects approximately 42 million U.S. adults.  The symptoms include urinary urgency, frequency and urge incontinence.  We also offer Macroplastique®, an injectable urethral bulking agent for the treatment of adult female stress urinary incontinence primarily due to intrinsic sphincter deficiency. For more information on the company and its products, please visit Uroplasty, Inc. at www.uroplasty.com.

For Further Information:
Uroplasty, Inc.
Brett Reynolds, SVP and CFO
952.426.6152

EVC Group
Leigh Salvo (Investors)/Janine McCargo (Business Media)
415.568.9349/646.688.0245

©2012 PR Newswire. All Rights Reserved.

Powered by WorldNow